Research Inventory

Retatrutide is an investigational synthetic peptide developed as a once-weekly injectable candidate. It acts as a triple receptor agonist, simultaneously targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It is being researched for its potential to reduce appetite, slow gastric emptying, improve glycemic control, increase energy expenditure, and promote substantial body weight reduction, along with possible benefits on metabolic health, fat mass, and lipid profiles. As of 2026, Retatrutide remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is in late-stage clinical development.

Ipamorelin is an investigational synthetic pentapeptide that acts as a selective ghrelin receptor agonist. It is studied primarily as an injectable candidate. It is being researched for its potential to stimulate growth hormone release, supporting muscle growth, fat metabolism, recovery, and body composition. As of 2026, Ipamorelin remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.

Tesamorelin is a synthetic 44-amino acid peptide analogue of growth hormone-releasing hormone (GHRH). It is approved by the TGA specifically for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy and is administered as a once-daily subcutaneous injection. It remains unapproved for other indications. It is also researched for its effects on growth hormone levels and visceral fat reduction.

MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is an investigational synthetic 16-amino acid peptide derived from the mitochondrial genome. It is studied primarily as an injectable candidate. It is being researched for its potential roles in regulating metabolic homeostasis, improving insulin sensitivity, enhancing glucose and fat metabolism, promoting mitochondrial function, and acting as an exercise mimetic. Additional areas of interest include support for energy production, reduction of age-related metabolic decline, and possible benefits in obesity, diabetes, and physical performance. As of 2026, MOTS-C remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.

Semax is an investigational synthetic heptapeptide developed as a nasal spray or injectable candidate. It is a synthetic analogue of a fragment of adrenocorticotropic hormone (ACTH 4-10). It is being researched for potential nootropic effects (improved cognition, memory, attention, and learning), neuroprotective properties (including in stroke or ischemia models), and possible mood or stress support. As of 2026, Semax remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is primarily available for research purposes.

Selank is an investigational synthetic heptapeptide developed as a nasal spray or injectable candidate. It is a synthetic analogue of the human immunomodulatory peptide tuftsin. It is being researched for potential anxiolytic (anti-anxiety), nootropic (cognitive enhancement, focus, memory), and neuroprotective effects, as well as possible immunomodulatory and stress-resilience properties. As of 2026, Selank remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is primarily available for research purposes.

DSIP (Delta Sleep-Inducing Peptide) is an investigational synthetic nonapeptide developed as an injectable candidate. It is a synthetic version of a naturally occurring neuropeptide first isolated from rabbit cerebral venous blood. It is being researched for potential effects on sleep regulation (particularly deep/slow-wave sleep), stress modulation, and nervous system recovery. As of 2026, DSIP remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.

MT2 (Melanotan II) is an investigational synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is studied primarily as an injectable candidate. It is being researched for its melanotropic effects (skin pigmentation/tanning) and potential influences on libido or erectile function. As of 2026, MT2 remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.

GHK-Cu (Glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper complex found in human plasma. It is widely used in topical cosmetic formulations and studied as an investigational injectable candidate for tissue repair applications. It is being researched for potential skin regeneration, wound healing, collagen production, anti-inflammatory, antioxidant, and tissue remodeling effects. As of 2026, injectable GHK-Cu remains unapproved by the TGA for general therapeutic use.

TB-500 (Thymosin Beta-4 fragment) is an investigational synthetic heptapeptide derived from the naturally occurring protein thymosin beta-4. It is studied primarily as an injectable candidate. It is being researched for potential roles in tissue repair, wound healing, angiogenesis (blood vessel formation), muscle and tendon recovery, and anti-inflammatory or regenerative processes. As of 2026, TB-500 remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.

BPC-157 (Body Protection Compound-157) is an investigational synthetic pentadecapeptide derived from a sequence found in human gastric juice. It is studied primarily in preclinical models as an injectable or oral candidate. It is being researched for potential tissue repair, wound healing, and regenerative effects on muscles, tendons, ligaments, and gastrointestinal tissues, along with possible anti-inflammatory and cytoprotective properties. As of 2026, BPC-157 remains unapproved by the Therapeutic Goods Administration (TGA) for general use and is classified as a research chemical.